Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNGVIR: Nivolumab/Ipilimumab + Chemo in NSCLC with HIV, HBV, HCV, or Long COVID
NCT05597800Phase 2Not yet recruiting
- Sponsor
- Università degli Studi di Verona
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Università degli Studi di Verona. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05597800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597800.